Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study
Objective: To assess cognitive functioning in adolescents (12–17 years old) with schizophrenia during open-label treatment with paliperidone extended-release (pali ER). Methods: In this exploratory analysis, adolescents treated with pali ER (oral, flexibly dosed, 1.5–12 mg/day) underwent cognitive a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-06-01
|
| Series: | Schizophrenia Research: Cognition |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2215001319300289 |
| _version_ | 1819011676434857984 |
|---|---|
| author | Gahan Pandina Isaac Nuamah Timothy Petersen Jaskaran Singh Adam Savitz David Hough |
| author_facet | Gahan Pandina Isaac Nuamah Timothy Petersen Jaskaran Singh Adam Savitz David Hough |
| author_sort | Gahan Pandina |
| collection | DOAJ |
| description | Objective: To assess cognitive functioning in adolescents (12–17 years old) with schizophrenia during open-label treatment with paliperidone extended-release (pali ER). Methods: In this exploratory analysis, adolescents treated with pali ER (oral, flexibly dosed, 1.5–12 mg/day) underwent cognitive assessments at baseline and month 6 using a battery of cognitive tests validated in adolescents. Correlation analysis was used to explore the relationship between cognitive assessments and clinical symptoms (Positive and Negative Syndrome Scales [PANSS] and factors) and functionality (Children Global Assessment Scale [CGAS]) at baseline and at 6 months. Results: A total of 324 of 393 patients had evaluable neurocognitive data. Changes in cognition function tests from baseline to endpoint were generally small to modest, with improvement noted for most cognitive domains (motor speed, attention/working memory, verbal learning and memory, social cognition, speed of processing, executive functioning). No improvement was noted for visual learning and memory. At baseline, there were modest negative correlations between disorganized thoughts and most cognitive domains; these correlations persisted at 6 months. Other significant negative correlations at 6 months were between speed of processing and PANSS total score, positive symptoms, negative symptoms and uncontrolled hostility (p < 0.05). At 6 months, higher CGAS scores (improved functioning) positively correlated with speed of processing and executive functioning, especially among pali ER responders. Conclusions: In this large sample of adolescents with schizophrenia, frank cognitive deficits across multiple domains were observed. Treatment with pali ER over 6 months did not worsen neurocognitive functioning and was possibly associated with positive improvement in certain domains. Keywords: Cognitive functioning, Schizophrenia, Paliperidone-extended-release |
| first_indexed | 2024-12-21T01:31:57Z |
| format | Article |
| id | doaj.art-ab59f2ffe19d4ef4a89e2a9341a2aaa6 |
| institution | Directory Open Access Journal |
| issn | 2215-0013 |
| language | English |
| last_indexed | 2024-12-21T01:31:57Z |
| publishDate | 2020-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Schizophrenia Research: Cognition |
| spelling | doaj.art-ab59f2ffe19d4ef4a89e2a9341a2aaa62022-12-21T19:20:20ZengElsevierSchizophrenia Research: Cognition2215-00132020-06-0120Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety studyGahan Pandina0Isaac Nuamah1Timothy Petersen2Jaskaran Singh3Adam Savitz4David Hough5Janssen Research & Development LLC, NJ, USA; Corresponding author at: Janssen Research & Development, LLC, Raritan, NJ 08560, USA.Janssen Research & Development LLC, NJ, USAMassachusetts General Hospital Department of Psychiatry, MA, USAJanssen Research & Development LLC, NJ, USAJanssen Research & Development LLC, NJ, USAJanssen Research & Development LLC, NJ, USAObjective: To assess cognitive functioning in adolescents (12–17 years old) with schizophrenia during open-label treatment with paliperidone extended-release (pali ER). Methods: In this exploratory analysis, adolescents treated with pali ER (oral, flexibly dosed, 1.5–12 mg/day) underwent cognitive assessments at baseline and month 6 using a battery of cognitive tests validated in adolescents. Correlation analysis was used to explore the relationship between cognitive assessments and clinical symptoms (Positive and Negative Syndrome Scales [PANSS] and factors) and functionality (Children Global Assessment Scale [CGAS]) at baseline and at 6 months. Results: A total of 324 of 393 patients had evaluable neurocognitive data. Changes in cognition function tests from baseline to endpoint were generally small to modest, with improvement noted for most cognitive domains (motor speed, attention/working memory, verbal learning and memory, social cognition, speed of processing, executive functioning). No improvement was noted for visual learning and memory. At baseline, there were modest negative correlations between disorganized thoughts and most cognitive domains; these correlations persisted at 6 months. Other significant negative correlations at 6 months were between speed of processing and PANSS total score, positive symptoms, negative symptoms and uncontrolled hostility (p < 0.05). At 6 months, higher CGAS scores (improved functioning) positively correlated with speed of processing and executive functioning, especially among pali ER responders. Conclusions: In this large sample of adolescents with schizophrenia, frank cognitive deficits across multiple domains were observed. Treatment with pali ER over 6 months did not worsen neurocognitive functioning and was possibly associated with positive improvement in certain domains. Keywords: Cognitive functioning, Schizophrenia, Paliperidone-extended-releasehttp://www.sciencedirect.com/science/article/pii/S2215001319300289 |
| spellingShingle | Gahan Pandina Isaac Nuamah Timothy Petersen Jaskaran Singh Adam Savitz David Hough Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study Schizophrenia Research: Cognition |
| title | Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study |
| title_full | Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study |
| title_fullStr | Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study |
| title_full_unstemmed | Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study |
| title_short | Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study |
| title_sort | cognitive functioning in adolescents with schizophrenia treated with paliperidone extended release 6 month exploratory analysis from an open label single arm safety study |
| url | http://www.sciencedirect.com/science/article/pii/S2215001319300289 |
| work_keys_str_mv | AT gahanpandina cognitivefunctioninginadolescentswithschizophreniatreatedwithpaliperidoneextendedrelease6monthexploratoryanalysisfromanopenlabelsinglearmsafetystudy AT isaacnuamah cognitivefunctioninginadolescentswithschizophreniatreatedwithpaliperidoneextendedrelease6monthexploratoryanalysisfromanopenlabelsinglearmsafetystudy AT timothypetersen cognitivefunctioninginadolescentswithschizophreniatreatedwithpaliperidoneextendedrelease6monthexploratoryanalysisfromanopenlabelsinglearmsafetystudy AT jaskaransingh cognitivefunctioninginadolescentswithschizophreniatreatedwithpaliperidoneextendedrelease6monthexploratoryanalysisfromanopenlabelsinglearmsafetystudy AT adamsavitz cognitivefunctioninginadolescentswithschizophreniatreatedwithpaliperidoneextendedrelease6monthexploratoryanalysisfromanopenlabelsinglearmsafetystudy AT davidhough cognitivefunctioninginadolescentswithschizophreniatreatedwithpaliperidoneextendedrelease6monthexploratoryanalysisfromanopenlabelsinglearmsafetystudy |